Corporate Presentation November 2024 Update

Collaboration Propels Innovation Corporate Presentation | November 2024 1 Forward-Looking Statements Corporate Presentation | November 2024 2 Ichnos Glenmark Innovation (“IGI”) is an alliance between Glenmark Pharmaceuticals Limited ( “GPL”) and Ichnos Sciences Inc. ( “Ichnos”) for the purpose of collaborating with each other on the discovery and development of new molecules by leveraging on each other capabilities to achieve synergies around developing innovative pharmaceutical products. These materials have been prepared by IGI solely for informational purposes and are strictly confidential and may not be taken away, reproduced, or redistributed to any other person. This presentation is on drugs in clinical development and includes information from experiments and information that might be considered forward-looking. While these forward-looking statements represent our current judgment based on current information, please be aware they are subject to risks and uncertainties as development progresses that could cause actual results to differ materially. These materials also contain material, non-public information. In addition, these materials contain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. In these materials, the words “will,” “anticipate,” “expect,” “plan,” “potential,” and similar expressions identify forward- looking statements. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward- looking statements. Such forward-looking statements are based on numerous assumptions regarding IGI’s present and future business strategies and the environment in which IGI will operate in the future and must be read together with such assumptions. Predictions, projections, or forecasts of the economy or economic trends of the markets are not necessarily indicative of the future or likely performance of IGI, and the forecast financial performance of IGI is not guaranteed. IGI does not undertake any obligation to update these forward- looking statements to reflect events, circumstances, or changes in expectations after the date hereof or to reflect the occurrence of subsequent events. No representations or warranties are made as to the accuracy or reasonableness of such assumptions or projections or the forward-looking statements based thereon. This presentation does not constitute or form part of, and should not be construed as, directly or indirectly, any offer or intimation or inducement to sell or issue or an offer or any solicitation of any offer, to purchase or sell any securities, as defined. The information contained here is not a prospectus, statement in lieu of prospectus, advertisement, or any other offer. It is not IGI’s intention to provide, and you may not rely on these materials as providing, a complete or comprehensive analysis of the IGI’s financial position or prospects. The information contained in these materials has these materials has not been independently verified and is subject to verification, completion, and change without notice. The information contained in these materials is current as of the date hereof and is subject to change without notice, and its accuracy is not guaranteed. Accordingly, no representation or warranty, express or implied, is made or given by or on behalf of IGI, or any of its directors and affiliates or any other person, as to, and no reliance should be placed for any purposes whatsoever on, the fairness, accuracy, completeness or correctness of, or any errors or omissions in, the information contained herein or any other information, whether written or oral, transmitted or made available to you herewith. The IGI name and all related names, logos, product and service names and designs included in these materials are trademarks of IGI or its affiliates or licensors. All other names, logos, product and service names, and designs included in these materials are the trademarks of their respective owners. The distribution of these materials in certain jurisdictions may be restricted or affected by the laws of such jurisdictions. To the fullest extent permitted by applicable law, IGI disclaims any responsibility or liability for the violations of any such restrictions by any person. Corporate Presentation | November 2024 3 OUR MISSION “To provide curative therapies that extend and improve lives.” OUR VISION “We dare to imagine a world where cure is possible.” Clinical-Stage Biotechnology Company at the Forefront of Innovation in Oncology Fully Integrated Biotech • Core capabilities in biologics and small molecules • Global footprint: U.S., Switzerland and India • Shifting to outsourced biologics manufacturing 4 Biologics Discovery Engine • Proprietary protein engineering platform (BEAT®) Robust Pipeline • Clinical stage pipeline in Oncology • Engaging different types of immune cells • 2 Alliances Corporate Presentation | November 2024 BEAT®: Bispecific Engagement by Antibodies based on the TCR Highly Experienced Leadership Team Corporate Presentation | November 2024 5 30+ Products developed or launched 40+ Mergers, acquisitions, IPOs and other transactions LEADERSHIP TEAM PREVIOUS EXPERIENCE BY THE NUMBERS Cyril Konto, M.D. President and Chief Executive Officer Lida Pacaud, M.D. Chief Medical Officer Mario Perro, Ph.D. Head of Biologics Research Nagaraj Gowda, Ph.D. Head of Small Molecules Research Dean Thomas, LLM General Counsel Sebastien Chenuet, Ph.D. Head of Business Development Roberto Giovannini, Ph.D. Chief Process & Manufacturing Officer Eva Yuen Head of Finance Karishma Sipahimalani, Ph.D. Head of Human Resources 110+ Years combined experience in biotech and pharmaceuticals Dennis Purcell Founder of Aisling Capital and Former Senior Managing Partner Cyril Konto, M.D. President and Chief Executive Officer Ichnos Glenmark Innovation Lawrence Olanoff, M.D., Ph.D. Former President and COO Forest Laboratories V S Mani Global CFO Glenmark Pharmaceuticals Limited Alind Sharma Global CHRO of Glenmark Glenmark Pharmaceuticals Limited Glenn Saldanha Chairman & Managing Director Glenmark Pharmaceuticals Limited Accomplished Board of Directors With Track Record of Success Corporate Presentation | November 2024 6 Meet The Scientific Advisory Board Corporate Presentation | November 2024 7 Adam Cohen, M.D. Associate Professor of Medicine , Director Penn Medicine Sergio Giralt, M.D. Professor of Medicine, Head of Hematologic Memorial Sloan Kettering Cancer Center Lawrence Olanoff, M.D., Ph.D. Former President and COO Forest Laboratories Kumar Prabhash, M.D. Head of Solid Tumors Unit, Medical Oncology Tata Memorial Hospital Eugene Zhukovsky, Ph.D. Manager and Partner, ZM Scientific Carlos Gracia-Echeverria, Ph.D. Drug Discovery Scientist, Pharma Executive Cancer Research Horizons Wolf Hervé Fridman, M.D., Ph.D. Professor Emeritus of Immunology Universite Paris Cite Medical School, France IGI’s Roadmap 8 CY24 CY25 CY26 Formation of IGI Clinical Proof-of- Concept for ISB 1442 and/or ISB 2001 ISB 2001 Licensing IPO Capital Raise Corporate Presentation | November 2024 Multispecific antibodies and Small Molecule (SM) Modulators are Complementary and Will Drive the Next Wave of Innovation in Oncology Sudhakar A., J Cancer Sci Ther., 2009. DOI Chen DS et al. Immunity. 2013 DOI, with permission from Elsevier Corporate Presentation | November 2024 9 MULTISPECIFICS AND SMALL MOLECULE IMMUNOMODULATORS Targeting simultaneously multiple cell surface antigens on cancer and immune cells while modulating their intracellular pathways. ISB 1442 ISB 2001 GRC 65327 Next Wave TARGETED THERAPIES IMMUNO-ONCOLOGY BISPECIFIC ANTIBODIES CAR-T CELLS FC Function-based Tumor Killing Checkpoint and Innate Immunity Modulators CD3 T Cell Engagers Engineered T Cells 2010 s 1990 s 2014 2017 PIPELINE Corporate Presentation | November 2024 10 Oncology-Focused Pipeline to Drive Long-Term Value Growth 11 ASSET DESCRIPTION INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 STATUS ISB 2001 BCMA x CD38 x CD3 TREAT TM trispecific T-Cell Engager Multiple Myeloma PHASE 1 ORPHAN DRUG GRC 65327 Cbl-b Inhibitor Small Molecule Solid Tumors PRE-CLINICAL ISB 2301 IMMUNITE TM NK-Cell Engager Solid Tumors DISCOVERY CLINICAL ASSETS CANDIDATES Corporate Presentation | November 2024 Strategic Partnerships Outside of Oncology to Maximize Pipeline Value PRODUCTS DESCRIPTION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 STATUS Licensed to $320 million for upfront payment, development, regulatory and sales milestone payments, plus tiered royalties on global sales Telazorlimab ISB 830-X8/STR-310 OX40 antagonist Monoclonal Antibody SUCCESSFUL PHASE 2B* PRE-CLINICAL Licensed to €20.8 million for upfront payment. Plus development, regulatory and sales milestone payments, and tiered royalties on global sales ISB 880/ALM27134 IL-1RAP antagonist Monoclonal Antibody PHASE 1 12 Atopic Dermatitis Hidradenitis Suppurativa * A US IND for rheumatoid arthritis and other autoimmune indications is active Corporate Presentation | November 2024 Partnering-Ready Assets to Accelerate Short-Term Value Creation ASSET DESCRIPTION INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 STATUS ISB 1342 CD38 x CD3 BEAT® bispecific T-Cell Engager Multiple Myeloma PHASE 1 ORPHAN DRUG ISB 1442 CD38 biparatopic x CD47 BEAT® Myeloid-Cell Engager Multiple Myeloma; AML planned PHASE 1 ORPHAN DRUG CLINICAL ASSETS Corporate Presentation | November 2024 13 BEAT® Platform Corporate Presentation | November 2024 14 Fab Common Light Chain Heavy Chain Heterodimerization Interface T cell receptor T cell Cell membrane TCR α TCR β Biased Heterodimer Purification Fc Proprietary plug-and-play modular platform enables a plurality of multispecific configurations BEAT® TREAT TM Common variable light chain domain TCR constant beta TCR constant alphaIgG1 IgG3 Common constant light chain domain T cell receptor TCR  TCR  BEAT® Combines TCR Interface-Based Heavy Chain Pairing and Universal Light Chain to Streamline Multispecific Antibodies Generation TREAT : TR ispecific Engagement by Antibodies based on the TCR TCR /: T-cell receptor  and  subunits; Fc: fragment crystallizable; Fab: fragment antigen-binding; Ig: immunoglobulin Corporate Presentation | November 2024 15 BEAT® is a Clinically Proven Platform Enabling the Design and Production of Immune Cell Engagers with High Developability Properties Corporate Presentation | November 2024 16 HPLC-Size Exclusion (% monomer) 98.2 98.4 98.0 LC-Mass Spectrometry (% purity) 99.9 99.0 100 Titer CHO (g/L) 2.5 11* 10* Solubility without formulation (PBS, mg/ml) ≥ 50 ≥ 50 ≥ 50 Fab Common Light Chain Common Light Chain Fab IgG3 TCR Ca TCR Cb TAA 1 TAA 2 TAA 1 TAA 2 epitope 1 TAA 2 epitope 2 TAA 1 BEAT® (1+1) bispecific antibody TAA 2 TAA 3 TREAT TM trispecific antibody BEAT® (2+1) bispecific biparatopic antibody * High cell density seeding (process intensification) at proof-of-concept stage, demonstrated in 3L bioreactors Expression using optimized vector system led to the detection of 94% (LC-Mass Spectrometry) heterodimer in the cell culture supernatant prior to purification TAA: Tumor Associated Antigen Multispecific Antibodies Using Clinically Proven BEAT® platform are Tailored to Specific Biological Functions Corporate Presentation | November 2024 17 • Establish collaboration leveraging our BEAT technology, discovery and development capabilities • Create new opportunities in therapeutic areas within oncology, autoimmune diseases and beyond • Collaborate through discovery and license agreements, co-development or company creation. BEAT® (2 + 1) TREAT TRISPECIFIC ISB 2001 Platform welcome partnerships to: Enables design and development of bi/multispecific antibodies that unlock new biology (e.g., T cell, NK cells, macrophage engagers) by optimizing: • Affinity: low-medium-high combinations • Epitope: target/test several epitopes • Architecture: avidity, immune synapse size • Fc function: T cell: silent; non T cell: active – enhanced • Improved druggability and developability – rapid engineering ISB 1442 MHC: Major histocompatibility complex, CDC: Complement-Dependent Cytotoxicity ADCC: Antibody-Dependent Cell-mediated Cytotoxicity 18 Corporate Presentation | November 2024 ISB 2001 ISB 2001 – Executive Summary Corporate Presentation | November 2024 19 • First-in-class trispecific BCMAxCD38xCD3 antibody, developed in relapsed/refractory Multiple Myeloma • Phase 1 first-in-human study of ISB 2001 for the treatment of relapsed/refractory multiple myeloma is currently ongoing in the US, Australia and India (Clinicaltrials.gov identifier: NCT05862012). • Preliminary results from the phase 1 dose escalation (ongoing) showed: o Overall response rate (ORR) of 75% (9/12) in efficacy-evaluable patients, including one (1) MRD negative stringent complete response. o Favorable safety and tolerability profile that showed no dose-limiting toxicities (DLTs), mild CRS, no ICANS, only one adverse event of special interest above Grade 2, and no treatment discontinuation. • Pre-clinical data1 showed potential for ISB 2001 to induce enhanced cytotoxicity relative to teclistamab against MM expressing variable levels of BCMA and CD38, mimicking naturaltumor heterogeneity. • Granted orphan drug designation (ODD) by the U.S. Food and Drug Administration (FDA). • ASH 2024 Oral Presentation2: First results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) 1Carretero-Iglesia L. et al. Nature Cancer 2024 DOI 2Abstract #1026, Monday, December 9, 2024, at 5:45 PM ISB 2001 Clinical Positioning Addresses Unmet Needs in Multiple Myeloma, Overcomes Limitations of Select Therapies HIGH UNMET NEED AND LARGE MARKET Global multiple myeloma cases annually1 LIMITATIONS OF SELECT THERAPIES • Decreased CD38 expression limits efficacy of CD38- targeted therapies3 • Resistance to Complement Dependent Cytotoxicity • Few options following failure of BCMA-targeted therapies 1 Ludwig H. et al, Oncologist 2020 DOI 2 Gandhi UH et al. Leukemia 2019 DOI 3 Saltarella I. et al., Cells 2020 DOI Corporate Presentation | November 2024 20 160000 Low Responses for Triple Refractory Patients2 3.4 9.3 31% ORR with subsequent therapy Median OS (months) Median PFS (months) ISB 2001 (BCMAxCD38xCD3): First TREAT TM Trispecific Antibody for Relapsed/Refractory Multiple Myeloma Corporate Presentation | November 2024 21 TREAT TMISB 2001 (BCMAxCD38x CD3) trispecific antibody • Three proprietary fragment antigen-binding arms: CD3ε on T cells; BCMA and CD38 on Multiple Myeloma cells • Heterodimerisation based on the BEAT platform in a TREATTM format • Fab domains derived from synthetic phage display library with common light chain (Vκ3-15 + IgκJ1) • Increased binding specificity to Multiple Myeloma cells due to enhanced avidity-based binding of anti-BCMA and anti-CD38 Fab domains • FDA/HREC clearance and a first-in-human study started in November 2023 • Granted Orphan Drug Designation by FDA Key Attributes ISB 2001: A Testament to IGI R&D Excellence Recognized by International Peer-Reviewed Journals and Conferences 1 Pihlgren M. et al. Blood (2022) DOI; 2 Carretero-Iglesia L. et al. Nature Cancer (2024) DOI 3 Ruuls S. et al. Nature Cancer (2024) DOI Corporate Presentation | November 2024 22 November First -in-Human March Clinical Candidate Selection 2023 Oral Presentation 2022 Oral Presentation (pre-clinical)1 2024 Manuscript2 Commentary by Paul Parren3 “ Antibody avidity meets multiple myeloma” Oral Presentation (clinical) June Proof -of Concept ISB 2001 Designed to Mediate Potent MM Cell Killing via Dual Targeting Avidity-Driven Tumor Binding Corporate Presentation | November 2024 23 Potency LO HI TECLISTAMAB IgG4 LALA ALNUCTAMAB IgG1 PG-LALA EM-801 IgG1 PG-LALA CD3 VH or VL BCMA VH or VL CD38 VH or VL ISB 2001 IgG1 PA-LALA Expression sABC CD38 expression (sABC) BCMA expression (sABC) Clinical case modelling KMS-12-BM LOW 28000 LOW 9000 Post treatment with daratumumab + teclistamab NCI-H929 MID 85000 MID 52000 Newly Diagnosed or post IMIDs + PI MOLP-8 HIGH 512000 VERY LOW 3200 Post BCMA targeted therapy KMS-12-BM (BCMAlow CD38low) NCI-H929 (BCMAint CD38int) MOLP-8 (BCMAlow CD38high) NQ: Not Quantifiable DU: Dummy (irrelevant binder) Carretero-Iglesia L. et al. Nature Cancer (2024) DOI; ISB 2001 Exhibits Desirable PK and shows 100% Complete Responses In Vivo in a BCMAlow CD38low Multiple Myeloma Model Corporate Presentation | November 2024 24 Efficacy in NSG-PBMC transfer Mouse Model (KMS-12-BM)ISB 2001 Half-Life in Tg32 (huFcRn Tg) Mice Molecule Half-Life (days) Cmax (µg/ml) AUC (µg.days/ml) ISB 2001 7.6 ± 0.9 95 ± 26 417 ± 75 Treatment Complete Response Teclistamab 0% (0/8 mice) ISB 2001 100% (8/8 mice) 16 November 2024Carretero-Iglesia L. et al. Nature Cancer (2024) DOI ISB 2001 Enhances Anti-Tumour Activity In Vitro and In Vivo Compared to BCMA and CD38 targeted therapies alone or in Combination 16 November 2024Corporate Presentation | November 2024 25 ISB 2001 is significantly more potent than Teclistamab + Daratumumab combination Treatment Complete response % of cured mice 2-way ANOVA vs ISB 2001 Vehicle 0/10 0 % **** ISB2001 8/9 89 % N.A. Teclistamab 3/11 27 % **** Daratumumab 0/9 0 % **** Teclistamab + Daratumumab 3/10 30 % **** CD34+ hHSC NSG mice Paired one-way ANOVA followed by Tukey’s multiple comparisons test Carretero-Iglesia L. et al. Nature Cancer (2024) DOI ISB 2001-101 Phase 1 Clinical Trial Design n = number of subjects. Key Patient Eligibility Criteria: • R/R MM with measurable disease after a CD38 antibody, IMiDs, PIs, and who must not be candidates for regimens known to provide clinical benefit • Failed 3 or more prior lines of therapies Primary Objectives: • Assess safety, tolerability • Determine MTD/RP2D Secondary Objectives: • PK, immunogenicity • Assess preliminary clinical activity of ISB 2001 Exploratory Objectives: • Assess biomarkers and their correlation with clinical activity, safety, and other clinical endpoints of interest • Assess minimal residual disease (MRD) when indicated Part 2: Expansion Cohort (n ≈ 80) Randomization 1:1:1 Cohort A: Dose 1 q1w (n=30, including 15 pts with PTDT) Cohort B: Dose 2 q1w (n=30, including 15 pts with PTDT) Cohort C: Dosing Schedule Optimization (n=20, including 10 pts with PTDT) Part 1: Dose Escalation (n ≈ 40) Accelerated Titration Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 Single Patient Dose Escalation 3+3 Dose Escalation until MTD or MFD Dose Level 9 Standard Titration Corporate Presentation | November 2024 26 Hanson S. et al. Blood (2023) DOI DLT: dose-limiting toxicity; MFD: maximum feasible dose; MTD: maximum tolerated dose; PTDT: post T-cell directed therapy; IMiDs: immuno-modulatory agents; PI: proteasome inhibitors; pts: patients First Clinical Results of the Ongoing ISB 2001-101 Phase 1 Study Corporate Presentation | November 2024 27 • Multicenter global Phase 1 dose-escalation study of ISB 2001 in patients with relapsed/refractory multiple myeloma will be presented in an oral session at the upcoming ASH24 Annual Meeting (Abstract) • Heavily pretreated patient population: median age was 66 years, with a median of 4 prior lines of therapy (range: 2-10). All patients were triple-exposed; 9 were penta-exposed, including 3 who were penta-refractory. • Overall, ISB 2001 was well tolerated and no DLT were observed. o Mostly mild CRS occurred in 71% (10 out of 14) of the patients: all were Grade 1, except one Grade 2 event, tocilizumab was used in 3 patients. o No ICANS. • Overall Response Rate (ORR) was 75% (9 of 12 efficacy-evaluable pts) across all doses. o 1 patient achieved MRD-negative stringent Complete Remission o ORR in doses ≥ 50 ug/kg was 90%. o All 9 subjects responding were still on treatment at data extract. • Dose escalation is ongoing with participants currently enrolling in DL8 (1800 µg/kg). Above results are based on data extracted on 29 July 2024 from14 patients treated with ISB 2001 at 5 µg/kg (n=1), 15 µg/kg (n =1), 50 µg/kg (n=1), 150 µg/kg (n =4), 300 µg/kg (n =3) or 600 µg/kg (n=4) who received at least one cycle of ISB 2001. GRC 65327 28 Corporate Presentation | November 2024 GRC 65327 – Executive Summary Corporate Presentation | November 2024 29 • Selective, small molecule, orally available, Cbl-b inhibitor, phase I-ready for solid tumor indications. • Demonstrated nM Cbl-b activity, >20-fold selectivity, potentiation of IL-2 and IFN-γ and T cells proliferation. • Robust immunomodulatory activity by reversing CD28 low T-cell exhaustion and Tumor cells killing • Significant tumor growth inhibition as a monotherapy and in combination with anti-PD1, while also inducing durable complete responses associated with memory immune responses. • An increased cellularity in mesenteric lymph nodes, a tissue immune response was noted at very low exposures (AUC ~1500 ng.h/mL) in a 1-month GLP monkey toxicology study. • FIH based on theoretical HNSTD in dogs as 10 mg BID (20 mg total dose/day) • IND submission to DCGI completed in October 2024 Choudhary et al., SITC 2024, poster presentation; DOI GRC 65327 Demonstrates Potent Immune-Stimulatory Activity Choudhary et al., SITC 2024, poster presentation; DOICorporate Presentation | November 2024 30 Basal 0.01 0.1 0.3 1 3 10 0 5000 10000 15000 20000 -CD3/28 Ab GRC65327 (µM) ✱✱✱✱ ✱✱✱✱ ✱✱✱✱ ✱✱✱✱ ✱✱✱✱ Basal 0.01 0.1 0.3 1 3 10 0 1000 2000 3000 4000 5000 -CD3/28 Ab GRC65327 (µM) ✱✱✱ ✱✱✱✱ ✱✱✱✱ ✱✱✱✱ ✱✱✱ ✱✱ Basal 0.01 0.1 0.3 1 3 10 0 500 1000 1500 -CD3/28 Ab GRC65327 (µM) ✱✱✱✱ ✱✱✱✱ ✱✱✱✱ ✱✱✱✱ ✱ Basal 0.01 0.1 0.3 1 3 10 0 5000 10000 15000 -CD3/28 Ab GRC65327 (µM) ✱✱✱ ✱✱✱✱ ✱✱✱✱ ✱✱✱✱ ✱✱ IL-2 (pg/mL) IFN-γ (pg/mL) Human PBMCs IL-2 (pg/mL) IFN-γ (pg/mL) Mouse splenocytes Human PBMCs (upper panel) & mouse splenocytes (lower panel) were treated with GRC 65327 and stimulated with anti-CD3 and anti- CD28 antibodies; cytokine release in supernatant was detected by sandwich ELISA. Statistical significance of differences was evaluated by Dunnett’s multiple comparison test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p< 0.0001 16 November 2024Corporate Presentation | November 2024 31 GRC 65327 Facilitates Robust Immune-Mediated Tumor Cell Killing co-culture 0.01 0.1 0.3 1 3 1 0 20 40 60 80 100 % killing (Tumor cells) GRC 65327 (µM) HCT-116(3D) + CD8 T cells resting + CD3+CD28 NX-1607 (µM) **** **** **** **** **** co-culture 0.01 0.1 0.3 1 3 1 0 20 40 60 80 100 % killing (Tumor cells) GRC 65327 (µM) HCT-116 + CD8 T cells exhausted + CD3+CD28 NX-1607 (µM) **** **** **** **** **** **** A B C D Human purified resting T cells and exhausted T cells were co-cultured with HCT116 spheroids in the presence of GRC 65327 and anti-CD3 and anti-CD28 antibodies stimulation (A). Microscopic images of spheroid – CD8 T cells co-culture with different concentrations of GRC 65327 (B). Percent tumor cell killing mediated by exhausted CD8 T-cells (C) and resting T-cells (D). Statistical significance of differences was evaluated by Dunnett’s multiple comparison test. **** p< 0.0001 Choudhary et al., SITC 2024, poster presentation; DOI GRC 65327 Enhances Anti-Tumor Immune Response as a Single Agent and in Combination with Anti-PD1 in the CT26 Tumor Model 16 November 2024Corporate Presentation | November 2024 32 • 0.1 million CT26 cells were implanted subcutaneously into female BALB/c mice • Animals were randomized when tumor volume reached ~50 mm3 • Doses: GRC 65327 dosed PO twice daily at 30 mg/kg, anti-PD1 antibody dosed IP BIW at 200µg/mouse. Statistics: 2-Way ANOVA followed by Bonferroni test **p<0.01, ***p<0.001 ****p<0.0001 Effective as a monotherapy, GRC 65327 achieved 7-9 complete responses in combination with anti-PD1 5 10 15 20 25 30 0 400 800 1200 Days post-CT26 cells injection Tumor volume (mm3) Vehicle GRC 65327 30 mg/kg PO BID (61% TGI, 2 CRs) **** GRC 65327 + anti-PD1 (79% TGI, 8 CRs) ****** anti-PD1 200ug/mouse Q4D (40% TGI, 5 CRs) **** Choudhary et al., SITC 2024, poster presentation; DOI 16 November 2024Corporate Presentation | November 2024 33 GRC 65327 Demonstrates Ability To Shape TME Via Biomarker Modulation 0 10 20 30 40 NOTCH1+ cells (%CD8) ** ** *** # Comparison CD3 treated vs Treatments+CD3; **p<0.01; ***p<0.001 One-Way ANOVA followed by Dunnett's multiple comparisons test, 1.3x 1.5x 2.4x 2.4x 1.5x 2.5x Naive CD3 Control 1 5 15 30 60 100 GRC 65327 Dose + αCD3 (700ng) Basal 0.01 0.1 0.3 0.6 1 30 10 20 30 40 50 % Notch/CD8 T-Cell GRC 65327 (µM) -CD3 antibody **** **** **** **** **** Basal 0.01 0.1 0.3 0.6 1 30 10 20 30 40 50 % Notch/CD4 T-Cell GRC 65327 (µM) -CD3 antibody **** **** **** **** **** A B C Human PBMCs were pre-treated with GRC 65327, followed by stimulation with anti-CD3 antibody. Surface expression of Notch1 on CD4 (A) and CD8 T-cells (B). Mice were treated orally with GRC 65327 followed by anti-CD3 antibody IP. Spleen was harvested to measure modulation of Notch1 on CD8 T-cells post 24 h dosing (C). Statistical significance of differences was evaluated by Dunnett’s multiple comparison test. **p<0.01, ***p<0.001, ****p<0.0001 Choudhary et al., SITC 2024, poster presentation; DOI American Society of Hematology 2024 Annual Meeting Corporate Presentation | November 2024 34 IGI Oral Presentation And Poster At The American Society Of Hematology 2024 Annual Meeting Corporate Presentation | November 2024 35 ISB 2001 Oral Presentation : First results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Presenter: Hang Quach, M.B.B.S, Professor of Haematology, University of Melbourne and Director of Clinical Haematology and Clinical Haematology Research, St. Vincent’s Hospital Melbourne Session Name: 654. Multiple Myeloma: Pharmacologic Therapies: Into the Future: New Drugs and Combinations in Multiple Myeloma Date & Time: Monday, December 9, 2024, at 5:45 PM Room: San Diego Convention Center, Hall B ISB 1442 Poster Presentation : Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Presenter: Binod Dhakal, M.D., M.S., Associate Professor of Medicine, Medical College of Wisconsin, Division of Hematology Session Name: 654. Multiple Myeloma: Pharmacologic Therapies: Poster II Presentation Date & Time: Sunday, December 8, 2024, 6:00-8:00 PM Room: San Diego Convention Center, Halls G-H Accomplishments 36 ISB 2001 Trispecific T-Cell Engager: Achieved Clinical Proof-of-Concept ISB 1442 Myeloid-Cell Engager: Program Discontinued GRC 65327 Cbl-b Inhibitor: IND Submission Completed with DCGI in India Alliance Formation: Partnership between Ichnos Sciences and Glenmark, Establishing IGI New Biologics Manufacturing Strategy: Shifting from In-House Production to Specialized CDMOs ASH24 Annual Meeting: First Presentation of Clinical Data with ISB 2001 Corporate Presentation | November 2024 37 Thank You! Together, Let’s Accelerate the Cure for Cancer Corporate Presentation | November 2024

The release as fetched from its publisher. iginnovate.com ↗